Compare Novartis AG (NVS) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Payoneer Global Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Payoneer Global Inc trades at $7.14 (market cap $2.43B). The key difference: Novartis AG is far larger — about 110.5× Payoneer Global Inc's market cap, and Novartis AG pays a 3.31% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Payoneer Global Inc for 61 Days on average.
| NVS | PAYO | |
|---|---|---|
Market Cap | $268.57B | $2.43B |
Volume | 1,532,573 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $168.62 | $7.18 |
52-Week Low | $121.80 | $4.27 |
Typical Hold Time | 82 Days | 61 Days |
Enterprise Value | $309.89B | $2.17B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, down 0.12% with a bearish technical signal. The stock shows strong fundamentals with 24.67% net margin and $14B net income, though recent earnings were mixed with a Q1 miss. Analyst consensus is cautious with 68% hold ratings and a $146 target. Recent $7.8B licensing deal with China's Abogen highlights strategic moves amid pipeline setbacks.
Outlook remains balanced: valuation metrics appear reasonable (P/E 21.6) and profitability is robust, but clinical trial failures and investor scrutiny over M&A strategy pose risks. The stock trades near consensus target with institutional sentiment leaning neutral amid ongoing pipeline execution challenges.
Payoneer Global (PAYO) trades at $7.16 with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q2 2026 earnings of $0.02 per share, missing estimates of $0.05761, though revenue grew 10% year-over-year excluding interest. Recent developments include the renewal of its partnership with Etsy through 2029 and expansion of its India innovation hub.
The pending acquisition by Nuvei creates uncertainty, but analyst sentiment remains positive with 60% buy ratings. Key risks include integration challenges from the acquisition and competitive pressures in the fintech sector, while opportunities lie in continued B2B growth and international expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
